AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Aurion Biotech.

    Client Virtual Booth

    AURION BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aurion Biotech
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Seattle, WA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aurionbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aurion-biotech/
    Twitter
    Twitter
    https://twitter.com/aurionbiotech

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial

    Details:

    AURN001 is a combination cell therapy product (biologic/drug) comprised of neltependocel & Y-27632 . It is being evaluated for the treatment of corneal edema secondary to corneal endothelial dysfunction.


    Lead Product(s): Neltependocel,Y27632

    Therapeutic Area: Ophthalmology Product Name: AURN001

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 30, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

    Details:

    AURN001 is a combination cell therapy product (biologic/drug) comprised of neltependocel & Y-27632 . It is being evaluated for the treatment of corneal edema secondary to corneal endothelial dysfunction.


    Lead Product(s): Neltependocel,Y27632

    Therapeutic Area: Ophthalmology Product Name: AURN001

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 28, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

    Details:

    AURN001 (CECs and Y-27632) is a combination cell therapy product and administered to the eye as a one-time, intracameral injection, which is investigated for the treatment of corneal edema secondary to corneal endothelial dysfunction.


    Lead Product(s): Neltependocel,Y27632

    Therapeutic Area: Ophthalmology Product Name: AURN001

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    Details:

    Vyznova is a human corneal endothelial cell therapy which involves taking healthy corneal cells from donor corneas and culturing them to produce off-the-shelf, fully differentiated CEC making it a potential treatment paradigm for corneal endothelial disease.


    Lead Product(s): Human Corneal Endothelial Cell Therapy

    Therapeutic Area: Genetic Disease Product Name: Vyznova

    Highest Development Status: ApprovedProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-handels-gmbh-m-2024-05-20

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search